Unknown

Dataset Information

0

In vivo evaluation of two tissue transglutaminase PET tracers in an orthotopic tumour xenograft model.


ABSTRACT: BACKGROUND:The protein cross-linking enzyme tissue transglutaminase (TG2; EC 2.3.2.13) is associated with the pathogenesis of various diseases, including cancer. Recently, the synthesis and initial evaluation of two high-potential radiolabelled irreversible TG2 inhibitors were reported by us. In the present study, these two compounds were evaluated further in a breast cancer (MDA-MB-231) tumour xenograft model for imaging active tissue transglutaminase in vivo. RESULTS:The metabolic stability of [11C]1 and [18F]2 in SCID mice was comparable to the previously reported stability in Wistar rats. Quantitative real-time polymerase chain reaction analysis on MDA-MB-231 cells and isolated tumours showed a high level of TG2 expression with very low expression of other transglutaminases. PET imaging showed low tumour uptake of [11C]1 (approx. 0.5 percentage of the injected dose per gram (%ID/g) at 40-60 min p.i.) and with relatively fast washout. Tumour uptake for [18F]2 was steadily increasing over time (approx. 1.7 %ID/g at 40-60 min p.i.). Pretreatment of the animals with the TG2 inhibitor ERW1041E resulted in lower tumour activity concentrations, and this inhibitory effect was enhanced using unlabelled 2. CONCLUSIONS:Whereas the TG2 targeting potential of [11C]1 in this model seems inadequate, targeting of TG2 using [18F]2 was achieved. As such, [18F]2 could be used in future studies to clarify the role of active tissue transglutaminase in disease.

SUBMITTER: van der Wildt B 

PROVIDER: S-EPMC5970127 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>The protein cross-linking enzyme tissue transglutaminase (TG2; EC 2.3.2.13) is associated with the pathogenesis of various diseases, including cancer. Recently, the synthesis and initial evaluation of two high-potential radiolabelled irreversible TG2 inhibitors were reported by us. In the present study, these two compounds were evaluated further in a breast cancer (MDA-MB-231) tumour xenograft model for imaging active tissue transglutaminase in vivo.<h4>Results</h4>The metabol  ...[more]

Similar Datasets

| S-ECPF-GEOD-38814 | biostudies-other
| S-EPMC6831199 | biostudies-literature
| S-EPMC4741524 | biostudies-literature
| S-EPMC6379498 | biostudies-literature
| S-EPMC7682014 | biostudies-literature
| S-EPMC5783541 | biostudies-literature
| S-EPMC5564531 | biostudies-other
| S-EPMC5660163 | biostudies-literature
| S-EPMC10298009 | biostudies-literature
| S-EPMC4257311 | biostudies-literature